Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 492 Shares

by · The Cerbat Gem

Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) CEO Emily M. Leproust sold 492 shares of the firm’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $38.73, for a total value of $19,055.16. Following the transaction, the chief executive officer now directly owns 660,474 shares in the company, valued at approximately $25,580,158.02. This represents a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST traded down $1.31 on Friday, reaching $36.19. 2,398,386 shares of the company were exchanged, compared to its average volume of 954,786. The company has a 50-day moving average of $44.16 and a 200-day moving average of $45.17. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -10.71 and a beta of 2.34. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period in the prior year, the business posted ($0.75) earnings per share. The firm’s revenue for the quarter was up 24.1% compared to the same quarter last year. Equities analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc grew its holdings in Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock valued at $27,000 after purchasing an additional 580 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Twist Bioscience in the 4th quarter worth about $58,000. Westwood Holdings Group Inc. acquired a new stake in Twist Bioscience in the 4th quarter valued at about $657,000. Teza Capital Management LLC acquired a new stake in Twist Bioscience in the 4th quarter valued at about $204,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in Twist Bioscience during the fourth quarter worth about $238,000.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on TWST shares. Robert W. Baird lifted their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Guggenheim set a $50.00 price objective on shares of Twist Bioscience in a research note on Friday, March 28th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Finally, Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $54.10.

Check Out Our Latest Report on TWST

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Articles